ESTRO 2022 - Abstract Book

S936

Abstract book

ESTRO 2022

Materials and Methods Twenty-five patients with Head and Neck cancer proven histopathologically, after obtaining informed written consent were enrolled for the study. At screening, patients were required to have symptomatic oral mucositis (RTOG Grade 2 or above) and oral pain scores of at least 6 on an 11-point Likert scale at screening and each day before radiotherapy. Patients were administered bioadhesive oral spray three times a day and oral mucositis pain, dysphagia, and odynophagia were assessed in terms of severity and duration at 5 minutes,30 minutes,1,2,4, and 6 hours. Results During the screening, 64% of patients had Grade III and 36% had Grade II Oral mucositis. After treatment, Patients experienced a median 57.1% decrease in pain intensity immediately within 5 minutes lasting up to 30 minutes and 42.9% up to 2 hours. The median pain intensity score reached 3 points on Likert scale at 5 minutes following oral spray application and was maintained up to 1 hour (i.e., patients experienced an average 3-point decline in pain intensity from baseline to 1 hour after treatment). Regarding rescue medication, only paracetamol was used in a total of 2 patients (8 %) during the treatment period. Opioids were not used as a rescue medication in any of the patients. Only 3 patients (12%) had the necessity for the Nasogastric tube. Dysphagia improved in 22 patients (88%) from semisolids to solids consumption within 5 minutes and lasted up to 6 hours in 7 patients (28%) with p<0.05 at end of 6 hours. Whereas, odynophagia reduced within 5 minutes in 22 patients (88%) and lasted up to 4 hours in 6 patients (24) with p<0.05 at end of 4 hours. The mean difference in weight loss during the treatment ranged from 0.7kg to1.6kg. Conclusion The bioadhesive barrier-forming oral liquid is efficacious in reducing pain in patients with oral mucositis undergoing radical radiotherapy with or without chemotherapy for head-and-neck cancer and demonstrated its potential value in clinical application. The analgesic effect was immediate, clinically significant, and persisted for up to 6 hours. It is well tolerated and the trend towards less Nasogastric tube-dependency and a possible reduction in In-patient time is promising. O. Engel 1 , R. Rodríguez Romero 2 , R. Benlloch Rodríguez 1 , B. Gil Haro 1 , S. Santana Jiménez 1 , S. Córdoba Largo 1 , M. López Valcárcel 1 , M. Hernández Miguel 1 , P. Sarrión Rubio de la Torre 1 , J. Romero Fernández 1 1 University Hospital Puerta de Hierro, Radiation Oncology, Madrid, Spain; 2 University Hospital Puerta de Hierro, Radiation Protection and Medical Physics, Madrid, Spain Purpose or Objective Salivary gland tumors (SGT) are a heterogeneous group of tumors with different histologies. Standard treatment is surgery followed by radio or chemoradiotherapy in high-risk patient. The objectives is to determine overall survival (OS), local relapse-free survival (LRFS), nodal relapse-free survival (NRFS) and distant metastases-free survival (DMFS) in patients treated with postoperative radiotherapy (PORT). Materials and Methods From 2010-2020, 26 patients with SGT were treated. Mean age: 58 years (19-89). Male:15 p; female:11 p.TNM (AJCC 8th edition) stages: I-II (11p); III (3p); IVA/B (12p). No patients had distant metastases at the time of diagnosis. Most patients had positive margin resection (R1, 80%). Histology: ductal: 7p; mucoepidermoid: 4p; acinar cell: 4p; others: 11p. Mean RT dose to tumor bed was 63 Gy (60-70). Neck nodes were irradiated in 22p (17 ipsilateral, 5 bilateral). Twelve patients received cisplatin-based concomitant chemotherapy. Statistic Kaplan-Meier, log-rank Results With mean follow up of 41 months (1-129) 5-year OS, LRFS, NRFS and DMFS were 48.6%, 92 %, 82.6% and 54.4%, respectively. Patients with pT3pT4 had more probability of vascular invasion (p=0,018) and more likely had cervical nodes involvement (p=0,019). PO-1103 Results of postoperative radiotherapy in salivary gland tumors: a 10-years’ experience